Complete financial analysis of SOPHiA GENETICS SA (SOPH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SOPHiA GENETICS SA, a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
You may be interested
- EQTEC plc (EQT.L) Income Statement Analysis – Financial Results
- Sino ICT Holdings Limited (0365.HK) Income Statement Analysis – Financial Results
- TUI AG (TUI1.DE) Income Statement Analysis – Financial Results
- Cera Sanitaryware Limited (CERA.BO) Income Statement Analysis – Financial Results
- Justiss Oil Co (JSTS) Income Statement Analysis – Financial Results
SOPHiA GENETICS SA (SOPH)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.sophiagenetics.com
About SOPHiA GENETICS SA
SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 62.37M | 47.56M | 40.45M | 28.40M | 25.36M |
| Cost of Revenue | 19.46M | 16.31M | 15.23M | 10.71M | 7.53M |
| Gross Profit | 42.91M | 31.25M | 25.22M | 17.69M | 17.83M |
| Gross Profit Ratio | 68.80% | 65.71% | 62.35% | 62.29% | 70.30% |
| Research & Development | 36.97M | 35.37M | 26.58M | 18.59M | 15.02M |
| General & Administrative | 53.30M | 55.82M | 41.51M | 18.97M | 15.67M |
| Selling & Marketing | 28.42M | 28.27M | 28.74M | 17.43M | 19.41M |
| SG&A | 81.72M | 84.08M | 70.24M | 36.40M | 35.08M |
| Other Expenses | -954.00K | -377.00K | -108.00K | -129.00K | 16.00K |
| Operating Expenses | 117.74M | 119.08M | 96.71M | 54.86M | 50.12M |
| Cost & Expenses | 137.20M | 135.38M | 111.94M | 65.57M | 57.65M |
| Interest Income | 4.55M | 1.32M | 20.00K | 96.00K | 86.00K |
| Interest Expense | 588.00K | 639.00K | 658.00K | 840.00K | 976.00K |
| Depreciation & Amortization | 8.34M | 5.57M | 3.61M | 2.39M | 1.91M |
| EBITDA | -70.70M | -82.67M | -70.84M | -38.76M | -30.74M |
| EBITDA Ratio | -113.35% | -172.94% | -167.76% | -122.11% | -119.42% |
| Operating Income | -74.83M | -87.82M | -71.49M | -37.17M | -32.29M |
| Operating Income Ratio | -119.97% | -184.66% | -176.73% | -130.86% | -127.30% |
| Total Other Income/Expenses | -3.67M | 238.00K | -2.02M | -3.84M | -1.34M |
| Income Before Tax | -78.50M | -87.59M | -73.51M | -41.23M | -33.63M |
| Income Before Tax Ratio | -125.85% | -184.16% | -181.72% | -145.16% | -132.60% |
| Income Tax Expense | 486.00K | -136.00K | 168.00K | -1.89M | 162.00K |
| Net Income | -78.98M | -87.45M | -73.68M | -39.34M | -33.79M |
| Net Income Ratio | -126.63% | -183.87% | -182.14% | -138.52% | -133.23% |
| EPS | -1.22 | -1.36 | -1.15 | -0.62 | -0.53 |
| EPS Diluted | -1.22 | -1.36 | -1.15 | -0.62 | -0.53 |
| Weighted Avg Shares Out | 64.75M | 64.10M | 63.86M | 63.86M | 63.86M |
| Weighted Avg Shares Out (Dil) | 64.75M | 64.10M | 63.86M | 63.86M | 63.86M |
Wall Street Analysts Think SOPHiA GENETICS (SOPH) Could Surge 64.95%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 65% in SOPHiA GENETICS (SOPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into...
SOPHiA GENETICS Reports First Quarter 2024 Results
Consistent Operational Execution; Robust New Business Momentum; Guidance Reaffirmed Consistent Operational Execution; Robust New Business Momentum; Guidance Reaffirmed
SOPHiA GENETICS to Present at the 2024 RBC Capital Markets Global Healthcare Conference
BOSTON and ROLLE, Switzerland, April 30, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced that Chief Financial Officer and Chief Operating Officer, Ross Muken, will present at the 2024 RBC...
SOPHiA GENETICS to Announce Financial Results for First Quarter 2024 on May 7, 2024
BOSTON and ROLLE, Switzerland, April 23, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter of fiscal year 2024 before U.S....
SOPHiA GENETICS Announces Syndicate Bio as First Liquid Biopsy Customer in Africa
Syndicate Bio to implement new liquid biopsy offering to advance cancer diagnostics throughout Africa BOSTON and ROLLE, Switzerland , April 23, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in...
SOPHiA GENETICS Announces Unilabs is using its AI Technology to Detect Homologous Recombination Deficiency (HRD)
European-based Unilabs has deployed the SOPHiA DDM™ Platform across its network in Switzerland to support cancer diagnostics and treatment BOSTON and ROLLE, Switzerland , April 17, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in...
SOPHiA GENETICS and Strand Life Sciences Announce New Strategic Partnership
The companies will join forces to advance the use of precision medicine on a global scale BOSTON and ROLLE, Switzerland , April 4, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader...
Laboratorio Barnafi-Krause is Live on SOPHiA DDM™
The Chile-based Laboratory is using SOPHiA GENETICS' platform to advance its research capabilities with blood disorders BOSTON and ROLLE, Switzerland , April 2, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced...
SOPHiA GENETICS Announces First Homologous Recombination Deficiency (HRD) Customer in Canada
University of Saskatchewan's (USask) Advanced Diagnostics Research Laboratory will use SOPHiA DDM™ Platform to advance research on ovarian cancer care BOSTON and ROLLE, Switzerland , March 20, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a...
SOPHiA GENETICS and The French Kidney Cancer Research Network (UroCCR) Publish Results from Multiyear Collaboration
New Multimodal Algorithm Highlights Predictive Benefit Of Artificial Intelligence (AI) for Cancer Research BOSTON and ROLLE, Switzerland , March 15, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, and the French Kidney...
Source: https://incomestatements.info
Category: Stock Reports